Arbutus Biopharma Corp Stock Current Valuation
| ABUS Stock | USD 2.75 0.11 4.17% |
Valuation analysis of Arbutus Biopharma Corp helps investors to measure Arbutus Biopharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to gain to about 417.2 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (5.44) in 2024. Fundamental drivers impacting Arbutus Biopharma's valuation include:
Price Book 4.9455 | Enterprise Value 356.6 M | Enterprise Value Ebitda (5.64) | Price Sales 28.9019 | Enterprise Value Revenue 22.0536 |
Undervalued
Today
Please note that Arbutus Biopharma's price fluctuation is unstable at this time. Calculation of the real value of Arbutus Biopharma Corp is based on 3 months time horizon. Increasing Arbutus Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Arbutus Biopharma Corp is useful when determining the fair value of the Arbutus stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Arbutus Biopharma. Since Arbutus Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Arbutus Stock. However, Arbutus Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.75 | Real 3.21 | Target 4.6 | Hype 2.77 |
The real value of Arbutus Stock, also known as its intrinsic value, is the underlying worth of Arbutus Biopharma Corp Company, which is reflected in its stock price. It is based on Arbutus Biopharma's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Arbutus Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Arbutus Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Arbutus Biopharma Corp helps investors to forecast how Arbutus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Arbutus Biopharma more accurately as focusing exclusively on Arbutus Biopharma's fundamentals will not take into account other important factors: Arbutus Biopharma Corp Company Current Valuation Analysis
Arbutus Biopharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Arbutus Biopharma Current Valuation | 356.58 M |
Most of Arbutus Biopharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arbutus Biopharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Arbutus Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Arbutus Biopharma is extremely important. It helps to project a fair market value of Arbutus Stock properly, considering its historical fundamentals such as Current Valuation. Since Arbutus Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arbutus Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arbutus Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Arbutus Current Valuation Historical Pattern
Today, most investors in Arbutus Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Arbutus Biopharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Arbutus Biopharma current valuation as a starting point in their analysis.
Arbutus Biopharma Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Arbutus Biopharma Corp has a Current Valuation of 356.58 M. This is 97.52% lower than that of the Biotechnology sector and 92.32% lower than that of the Health Care industry. The current valuation for all United States stocks is 97.86% higher than that of the company.
Arbutus Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arbutus Biopharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arbutus Biopharma could also be used in its relative valuation, which is a method of valuing Arbutus Biopharma by comparing valuation metrics of similar companies.Arbutus Biopharma is currently under evaluation in current valuation category among related companies.
Arbutus Biopharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Arbutus Biopharma from analyzing Arbutus Biopharma's financial statements. These drivers represent accounts that assess Arbutus Biopharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arbutus Biopharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 158.7M | 269.2M | 413.3M | 351.7M | 414.9M | 435.6M | |
| Enterprise Value | 130.3M | 219.9M | 306.6M | 323.1M | 397.3M | 417.2M |
Arbutus Fundamentals
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (9.57) % | ||||
| Current Valuation | 356.58 M | ||||
| Shares Outstanding | 180.18 M | ||||
| Shares Owned By Insiders | 23.34 % | ||||
| Shares Owned By Institutions | 43.92 % | ||||
| Number Of Shares Shorted | 4.55 M | ||||
| Price To Earning | (1.16) X | ||||
| Price To Book | 4.95 X | ||||
| Price To Sales | 28.90 X | ||||
| Revenue | 18.14 M | ||||
| Gross Profit | (45.39 M) | ||||
| EBITDA | (76.63 M) | ||||
| Net Income | (72.85 M) | ||||
| Cash And Equivalents | 150.2 M | ||||
| Cash Per Share | 1.00 X | ||||
| Total Debt | 8.72 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 5.29 X | ||||
| Book Value Per Share | 0.62 X | ||||
| Cash Flow From Operations | (85.94 M) | ||||
| Short Ratio | 7.05 X | ||||
| Earnings Per Share | (0.44) X | ||||
| Target Price | 4.4 | ||||
| Number Of Employees | 73 | ||||
| Beta | 2.09 | ||||
| Market Capitalization | 475.66 M | ||||
| Total Asset | 144.4 M | ||||
| Retained Earnings | (1.28 B) | ||||
| Working Capital | 109.54 M | ||||
| Current Asset | 183.88 M | ||||
| Current Liabilities | 10.58 M | ||||
| Net Asset | 144.4 M |
About Arbutus Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arbutus Biopharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arbutus Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arbutus Biopharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Arbutus Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Arbutus Biopharma's short interest history, or implied volatility extrapolated from Arbutus Biopharma options trading.
Pair Trading with Arbutus Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arbutus Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arbutus Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Arbutus Stock
| 0.56 | PCRX | Pacira Pharmaceuticals Earnings Call This Week | PairCorr |
| 0.48 | MGTX | MeiraGTx Holdings PLC Financial Report 9th of May 2024 | PairCorr |
| 0.41 | PFE | Pfizer Inc Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Arbutus Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arbutus Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arbutus Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arbutus Biopharma Corp to buy it.
The correlation of Arbutus Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arbutus Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arbutus Biopharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arbutus Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Arbutus Biopharma Piotroski F Score and Arbutus Biopharma Altman Z Score analysis. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Arbutus Stock analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is Arbutus Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arbutus Biopharma. If investors know Arbutus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arbutus Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Revenue Per Share 0.109 | Quarterly Revenue Growth (0.66) | Return On Assets (0.29) | Return On Equity (0.60) |
The market value of Arbutus Biopharma Corp is measured differently than its book value, which is the value of Arbutus that is recorded on the company's balance sheet. Investors also form their own opinion of Arbutus Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arbutus Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arbutus Biopharma's market value can be influenced by many factors that don't directly affect Arbutus Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arbutus Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Arbutus Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arbutus Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.